Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKS NASDAQ:BCRX NASDAQ:HALO NASDAQ:IONS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$52.89-0.2%$46.92$25.17▼$55.67$8.82B0.341.96 million shs1.29 million shsBCRXBioCryst Pharmaceuticals$9.34-0.4%$9.22$6.00▼$11.22$2.37B0.554.70 million shs1.85 million shsHALOHalozyme Therapeutics$81.93+1.3%$73.08$57.67▼$82.99$9.72B0.841.75 million shs1.66 million shsIONSIonis Pharmaceuticals$56.55+1.2%$71.60$40.03▼$86.74$9.35B0.364.45 million shs3.09 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes0.00%+0.32%+0.11%+58.78%+94.52%BCRXBioCryst Pharmaceuticals0.00%+0.54%-5.66%+4.47%+8.48%HALOHalozyme Therapeutics0.00%+5.29%+12.79%+25.35%+39.91%IONSIonis Pharmaceuticals0.00%+3.97%-27.81%-22.82%+33.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$52.89-0.2%$46.92$25.17▼$55.67$8.82B0.341.96 million shs1.29 million shsBCRXBioCryst Pharmaceuticals$9.34-0.4%$9.22$6.00▼$11.22$2.37B0.554.70 million shs1.85 million shsHALOHalozyme Therapeutics$81.93+1.3%$73.08$57.67▼$82.99$9.72B0.841.75 million shs1.66 million shsIONSIonis Pharmaceuticals$56.55+1.2%$71.60$40.03▼$86.74$9.35B0.364.45 million shs3.09 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes0.00%+0.32%+0.11%+58.78%+94.52%BCRXBioCryst Pharmaceuticals0.00%+0.54%-5.66%+4.47%+8.48%HALOHalozyme Therapeutics0.00%+5.29%+12.79%+25.35%+39.91%IONSIonis Pharmaceuticals0.00%+3.97%-27.81%-22.82%+33.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.72Moderate Buy$52.50-0.74% DownsideBCRXBioCryst Pharmaceuticals 2.67Moderate Buy$20.80122.70% UpsideHALOHalozyme Therapeutics 2.54Moderate Buy$81.60-0.40% DownsideIONSIonis Pharmaceuticals 2.77Moderate Buy$95.9069.58% UpsideCurrent Analyst Ratings BreakdownLatest BCRX, HALO, IONS, and ALKS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2026IONSIonis Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/21/2026HALOHalozyme Therapeutics BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/21/2026IONSIonis Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$106.00 ➝ $89.007/21/2026HALOHalozyme Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$95.007/20/2026ALKSAlkermes Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.00 ➝ $63.007/17/2026IONSIonis Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/16/2026IONSIonis Pharmaceuticals Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Peer Perform7/13/2026ALKSAlkermes Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$61.00 ➝ $62.007/13/2026ALKSAlkermes JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$60.007/13/2026BCRXBioCryst Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$12.007/13/2026IONSIonis Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$100.00 ➝ $85.00(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.48B5.97$1.67 per share31.59$11.02 per share4.80BCRXBioCryst Pharmaceuticals$885.72M2.68$1.24 per share7.54($0.57) per share-16.39HALOHalozyme Therapeutics$1.51B6.44$4.77 per share17.17$0.42 per share195.07IONSIonis Pharmaceuticals$1.06B8.83N/AN/A$3.02 per share18.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$241.66M$0.9058.77264.45N/A9.78%9.26%5.66%7/28/2026 (Estimated)BCRXBioCryst Pharmaceuticals$263.86M-$1.78N/A14.59N/A-51.71%-76.36%60.12%8/5/2026 (Estimated)HALOHalozyme Therapeutics$316.89M$2.7829.478.920.3423.13%187.91%21.92%8/6/2026 (Estimated)IONSIonis Pharmaceuticals-$381.39M-$2.07N/AN/AN/A-30.91%-58.65%-10.07%7/29/2026 (Estimated)Latest BCRX, HALO, IONS, and ALKS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026HALOHalozyme Therapeutics$1.82N/AN/AN/A$402.28 millionN/A8/5/2026Q2 2026BCRXBioCryst Pharmaceuticals$0.14N/AN/AN/A$183.28 millionN/A7/29/2026Q2 2026IONSIonis Pharmaceuticals-$1.0810N/AN/AN/A$189.10 millionN/A7/28/2026Q2 2026ALKSAlkermes-$0.04N/AN/AN/A$457.41 millionN/A5/11/2026Q1 2026HALOHalozyme Therapeutics$1.54$1.60+$0.06$1.22$358.60 million$376.71 million5/6/2026Q1 2026BCRXBioCryst Pharmaceuticals$0.06-$2.98-$3.04-$2.98$151.12 million$156.41 million4/29/2026Q1 2026IONSIonis Pharmaceuticals-$0.85-$0.56+$0.29-$0.56$195.57 million$246.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/ABCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermes0.852.271.70BCRXBioCryst PharmaceuticalsN/A1.911.88HALOHalozyme Therapeutics8.812.762.33IONSIonis Pharmaceuticals2.754.104.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%BCRXBioCryst Pharmaceuticals85.88%HALOHalozyme Therapeutics97.79%IONSIonis Pharmaceuticals93.86%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.59%BCRXBioCryst Pharmaceuticals3.80%HALOHalozyme Therapeutics2.50%IONSIonis Pharmaceuticals1.81%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes2,050166.68 million159.03 millionOptionableBCRXBioCryst Pharmaceuticals530254.16 million244.51 millionOptionableHALOHalozyme Therapeutics390118.61 million115.65 millionOptionableIONSIonis Pharmaceuticals1,402165.26 million162.27 millionOptionableBCRX, HALO, IONS, and ALKS HeadlinesRecent News About These CompaniesBank of New York Mellon Corp Sells 239,269 Shares of Ionis Pharmaceuticals, Inc. $IONSJuly 26 at 3:19 AM | marketbeat.comIonis Pharmaceuticals, Inc. $IONS Shares Purchased by KBC Group NVJuly 25 at 5:03 AM | marketbeat.comHow Eplontersen’s Phase 3 Setback And Scrutiny At Ionis Pharmaceuticals (IONS) Has Changed Its Investment StoryJuly 24 at 10:34 AM | finance.yahoo.comIonis Pharmaceuticals (IONS) Misses A Key Trial Endpoint, Is The Valuation Now Too Harsh?July 24 at 10:34 AM | finance.yahoo.comIonis Pharmaceuticals, Inc. $IONS Shares Acquired by California Public Employees Retirement SystemJuly 24 at 3:37 AM | marketbeat.comIonis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSSJuly 23 at 11:30 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONSJuly 23 at 10:00 AM | prnewswire.comHsbc Holdings PLC Acquires 159,026 Shares of Ionis Pharmaceuticals, Inc. $IONSJuly 23 at 4:47 AM | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Sees Unusually-High Trading Volume - Time to Buy?July 22, 2026 | marketbeat.comEarnings Preview: Ionis Pharmaceuticals (IONS) Q2 Earnings Expected to DeclineJuly 22, 2026 | zacks.comIonis Pharmaceuticals (IONS) Expected to Post Earnings on WednesdayJuly 22, 2026 | marketbeat.com114,334 Shares in Ionis Pharmaceuticals, Inc. $IONS Purchased by SEB Asset Management ABJuly 22, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONSJuly 21, 2026 | globenewswire.com25,886 Shares in Ionis Pharmaceuticals, Inc. $IONS Acquired by Florida Financial Advisors LLCJuly 21, 2026 | marketbeat.comIonis Pharmaceuticals' (IONS) "Peer Perform" Rating Reiterated at Wolfe ResearchJuly 19, 2026 | americanbankingnews.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 17, 2026 | americanbankingnews.comIonis Pharmaceuticals: The Heartbreak Is Priced InJuly 16, 2026 | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONSJuly 16, 2026 | prnewswire.comIonis Pharmaceuticals (NASDAQ:IONS) Given "Peer Perform" Rating at Wolfe ResearchJuly 16, 2026 | marketbeat.comIonis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSSJuly 15, 2026 | globenewswire.comBiogen Shares Decline After Detailed Diranersen Alzheimer's Study DataJuly 15, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026The Ugliest Stocks in the Market Just Got a Very Expensive Vote of ConfidenceBy Bridget Bennett | July 20, 2026Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to BenefitBy Dan Schmidt | July 19, 2026IQM's Nasdaq Debut Could Change the Quantum Race for D-WaveBy Nathan Reiff | July 10, 2026AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetBy Jeffrey Neal Johnson | July 10, 2026BCRX, HALO, IONS, and ALKS Company DescriptionsAlkermes NASDAQ:ALKS$52.89 -0.08 (-0.15%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$52.84 -0.05 (-0.09%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.BioCryst Pharmaceuticals NASDAQ:BCRX$9.34 -0.04 (-0.43%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$9.36 +0.02 (+0.24%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Halozyme Therapeutics NASDAQ:HALO$81.93 +1.09 (+1.35%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$81.50 -0.43 (-0.52%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Ionis Pharmaceuticals NASDAQ:IONS$56.55 +0.68 (+1.22%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$55.68 -0.88 (-1.55%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
